Sir Brian Roche says there is a concern about the level of analysis given to Treaty "breaches". Photo / Marty Melville There are too many meetings in the public service, too many layers of ...

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

If anything, the gap understates the gulf between the soft-spoken, beetle-browed Hoffmann, who is the great-grandson of Fritz Hoffmann-La Roche, founder of pharmaceuticals group Roche, and the ...

We explore the history of global pharmaceutical group Hoffmann-La Roche from where it first began, to its core structure and its focus for the future in personalised medicine. Roche was found in ...

Roche has a big problem. With competition threatening some of its older and most lucrative biologic drugs, the Swiss pharmaceutical giant expects that, between 2023 and 2028, sales from these assets ...

Roche Eyes Judicious Use of $10B M&A Budget Every year, Roche sets aside around $10 billion for potential M&A deals, but CEO Teresa Graham revealed at JPM25 that the pharma is selective in how and ...

Nearly 4,000 young Indonesians have taken up Singaporean citizenship in the past few years, driven by scholarships offered by the Singapore government and better career opportunities in the city ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback program ...